PIK3CA and cancer: Unfortunately, these inhibitors have shown limited efficacy in cancer in part due to the release of potent negative feedback loops causing compensatory overactivation of upstream signaling nodes, including PI3K, AKT and ERK that oppose the antiproliferative effects of the inhibitors.